Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Extended-release oxybutynin.

A M Comer1, K L Goa

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs & Aging
|April 8, 2000
PubMed
Summary
This summary is machine-generated.

Extended-release oxybutynin effectively treats detrusor instability by relaxing bladder muscles. This formulation offers comparable efficacy to immediate-release oxybutynin with a more convenient once-daily dosage.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Velnacrine in Alzheimer's Disease : An Initial Appraisal of its Clinical Potential.

CNS drugs·2016
Same author

Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

CNS drugs·2013
Same author

Adjuvanted influenza vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Liposomal influenza vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Follitropin alpha in infertility: a review.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same journal

Targeted Treatment for Hyperuricemia: The Drug Pipeline.

Drugs & aging·2026
Same journal

Efficacy and Safety of Ciprofol Versus Propofol for Anesthesia in Older Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Drugs & aging·2026
Same journal

Leveraging Real-World Data for Clinical Decision Making in Geriatric Oncology.

Drugs & aging·2026
Same journal

Drug Utilisation of Fall-Risk-Increasing Drugs (FRIDs) and Risk of Hospitalisation: A Nested Case-Control Study Among Community-Dwelling Older Adults.

Drugs & aging·2026
Same journal

Gabapentinoid Use and Risk of Alzheimer's Disease-Related Dementias: A Systematic Review and Meta-analysis of Observational Studies.

Drugs & aging·2026
Same journal

Development and Validation of Prescribing Appropriateness Criteria (PAC) for Sri Lankan Older Adults.

Drugs & aging·2026
See all related articles

Area of Science:

  • Pharmacology
  • Urology

Background:

  • Detrusor instability is a condition characterized by involuntary bladder muscle contractions.
  • Oxybutynin is an anticholinergic medication used to treat overactive bladder symptoms.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of extended-release oxybutynin (Ditropan XL) for treating detrusor instability.
  • To compare the pharmacokinetic profile of extended-release oxybutynin with immediate-release formulations.

Main Methods:

  • Randomized, double-blind clinical trials assessed efficacy over short durations (< or =6 weeks).
  • Pharmacokinetic studies compared plasma concentrations and bioavailability of extended-release versus immediate-release oxybutynin.
  • A large noncomparative study evaluated long-term adherence.

Related Experiment Videos

Main Results:

  • Extended-release oxybutynin (5-30mg once daily) significantly reduced weekly urge incontinence episodes by 84-90%.
  • Mean peak plasma concentrations were lower with extended-release oxybutynin compared to immediate-release formulation.
  • Relative bioavailability of parent drug and metabolite differed between formulations.
  • Adverse events were primarily dose-related anticholinergic effects (dry mouth, somnolence, constipation, blurred vision, dizziness).
  • Approximately two-thirds of patients remained on extended-release oxybutynin after 6 months.

Conclusions:

  • Extended-release oxybutynin is an effective treatment for detrusor instability, offering similar efficacy to immediate-release oxybutynin.
  • The osmotic-controlled release delivery system (OROS) provides a convenient once-daily dosing regimen.
  • Long-term adherence suggests good tolerability and patient acceptance of extended-release oxybutynin.